Send us Feedback

Pharmaceutical Resources (PRX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

PRX » Topics » SVC Pharma LP License and Distribution Agreement

This excerpt taken from the PRX 8-K filed Jun 19, 2009.

SVC Pharma LP License and Distribution Agreement

In June 2008, Par and SVC entered into a license and distribution agreement for dronabinol and related agreements.  Under the terms of the agreements, Par transferred 100% of its interest in SVC to Rhodes Technologies, and SVC became the sole owner of the ANDA for dronabinol.  In exchange, SVC granted Par the exclusive right and license to market, distribute and sell dronabinol in the United States for a term of approximately 10 years.  Par reclassified a portion of its investment in SVC to intangible assets, which represents the right and license to market dronabinol in the United States.  Par launched dronabinol during the third quarter of 2008.  Refer to Note 21 - “Investment in Joint Venture” for further details.  

These excerpts taken from the PRX 10-K filed Mar 2, 2009.

SVC Pharma LP License and Distribution Agreement

In June 2008, Par and SVC entered into a license and distribution agreement for dronabinol and related agreements.  Under the terms of the agreements, Par transferred 100% of its interest in SVC to Rhodes Technologies, and SVC became the sole owner of the ANDA for dronabinol.  In exchange, SVC granted Par the exclusive right and license to market, distribute and sell dronabinol in the United States for a term of approximately 10 years.  Par reclassified a portion of its investment in SVC to intangible assets, which represents the right and license to market dronabinol in the United States.  Par launched dronabinol during the third quarter of 2008.  Refer to Note 20 - “Investment in Joint Venture” for further details.  

SVC Pharma LP
License and Distribution Agreement


In June 2008,
Par and SVC entered into a license and distribution agreement for dronabinol and
related agreements.  Under the terms of the agreements, Par transferred
100% of its interest in SVC to Rhodes Technologies, and SVC became the sole
owner of the ANDA for dronabinol.  In exchange, SVC granted Par the
exclusive right and license to market, distribute and sell dronabinol in the
United States for a term of approximately 10 years.  Par reclassified a
portion of its investment in SVC to intangible assets, which represents the
right and license to market dronabinol in the United States.  Par launched
dronabinol during the third quarter of 2008.  Refer to Note 20 -
“Investment in Joint Venture” for further details.  


EXCERPTS ON THIS PAGE:

8-K
Jun 19, 2009
10-K (2 sections)
Mar 2, 2009

RELATED TOPICS for PRX:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki